Updated October 2026 · Written and maintained by the Progression Agency strategy team
Pharma email marketing is the planning, writing, review routing, sending and measurement of email from a drug, biotech or medical device manufacturer to healthcare professionals and to patients enrolled in a support program. At most brands the center of it is HCP email: promotional and medical messages to physicians, nurse practitioners, physician assistants and pharmacists, sent from the brand or by field reps through tools such as Veeva Approved Email. Progression builds these programs for brand, medical affairs and commercial teams, with every piece prepared for your medical, legal and regulatory review. Progression Agency is based in New York City and works with clients across the United States and worldwide.
On this page · 18 sections
- What is pharma email marketing, and who receives it?
- Pharma email best practices for HCP email that clinicians read
- What is Veeva Approved Email, and how does rep triggered email work?
- Patient support and adherence email
- How does MLR review shape a pharma email program?
- FDA rules that reach email
- Consent, CAN-SPAM, state rules and industry codes
- Where email sits in HCP marketing
- Segmenting by specialty, prescribing data and channel preference
- Deliverability to hospital and health system inboxes
- Measuring a pharma email program beyond opens
- Biotech email marketing before and after approval
- Medical device email marketing
- How AI assistants answer questions about pharmaceutical email marketing
- How to choose an agency for email marketing for pharma
- What Progression delivers, and what your MLR team owns
- How much does pharma email marketing cost?
- Related services for pharma, biotech and device teams
The short answerA pharma email program has three streams: HCP promotional and medical email, rep-sent email from approved templates, and patient support email for people who enrolled. Each is written from approved claims, carries fair balance and safety information, and passes your MLR review before it sends. We report clicks to approved resources, sample and rep requests and enrollments rather than opens, which privacy features inflate. A first program is usually live in eight to ten weeks, and the work is quoted after a written scope.
Prices are Progression’s published one-off, website and SEO prices; the email program itself is quoted after a written scope. Rules are named in the sections where they apply. This page is general information, not legal or regulatory advice.
What is pharma email marketing, and who receives it?
It is email sent by or for a manufacturer about its products, its disease areas or its support programs. The readers are licensed clinicians who opted in and patients or caregivers who enrolled in a program, never a purchased consumer list.
The three streams in one program
Brand teams usually run three kinds of pharma emails side by side. The first is home office email to HCPs: launch notes, new data, dosing and access updates. The second is rep-sent email, where a field representative chooses an approved template and sends it after a visit or call. The third is patient support email to people who enrolled in a copay, hub or adherence program. Each has its own audience, consent record, review path and success measure.
What is HCP email?
HCP email is email to healthcare professionals: physicians, nurse practitioners, physician assistants, pharmacists and, for some products, nurses and practice managers. It carries clinical and access information a prescriber can act on, so it is written to clinical standards and reviewed as promotional material when it mentions a product. HCP emails go only to verified professionals who agreed to receive them.
Who does not belong on the list
Rented consumer lists, scraped addresses and lists bought from data brokers without documented professional consent do not belong in a pharmaceutical email program. They damage sender reputation in hospital mail systems, they leave no consent trail, and they undermine the trust a brand is trying to build with prescribers. We do not sell, rent or source HCP lists.
| Stream | Sent by | Reader | Typical content | Success measure |
|---|---|---|---|---|
| Home office HCP email | Brand or medical team | Opted-in HCPs by specialty | Launch, data, dosing, access, events | Clicks to approved resources; requests |
| Rep-sent approved email | Field representative | HCPs the rep calls on | Follow-up to a visit, a resource, a sample offer | Replies, meetings, sample requests |
| Patient support email | Program or hub vendor | Enrolled patients and caregivers | Enrollment, onboarding, refill and copay notes | Completed enrollment; program retention |
| Medical information reply | Medical affairs | An HCP who asked a question | A response to an unsolicited request | Response time and completeness |
Pharma email best practices for HCP email that clinicians read
Clinicians skim email between patients, so the best pharma email makes one point, shows its safety information plainly and gives one clear next step. Everything else follows from respecting that reader’s time.
One clinical point per message
A message that covers efficacy, a new dosing schedule, a savings card and a webinar at once is hard to read and slow to review. Split them. One point per email gives the reader a reason to click and gives your reviewers one claim set to check, which shortens the review queue as well.
Subject lines and preheaders sit inside the claims
The subject line and preheader are part of the piece your reviewers approve. A subject that implies a benefit is a claim and needs the same support and balance as the body. Plain, specific subject lines such as a dosing update or a new resource usually test well with clinicians and pass review faster than clever ones.
Where safety information sits
When a promotional email names a product, the Important Safety Information belongs in the email itself, readable without scrolling past a wall of design, with a link to the full prescribing information. We set ISI in live text at a readable size rather than as an image, so it still appears when a hospital mail client blocks images.
Pharma email design for hospital inboxes
Good pharma email design uses a single column, live text, small images with alt text and a button that works on a phone. Many clinical mail systems strip or block remote images and scripts, so the message has to make sense with images off. Heavy animated files and image-only layouts are the most common reasons a well-reviewed email never gets read.
- Name the sender clearly: the brand, the company or the rep
- Keep the call to action single and specific
- Put the safety information in live text inside the email
- Link to the full prescribing information from every product email
- Test rendering with images off and in dark mode
- Send at a cadence agreed with your field team
- Retire a template on its expiry date, not when someone notices
- Record every send against the approved version number
- Keep medical information replies out of promotional sequences
- Share one suppression list across every sending tool
What is Veeva Approved Email, and how does rep triggered email work?
Veeva describes Approved Email as an application within Vault CRM that lets users send compliant emails to HCPs by assembling them from approved templates. Reps pick a template, add permitted personal touches and send; the content itself stays as approved.
How approved templates work
In an approved email setup, the brand team and its reviewers approve a template and its fixed content once. Reps then choose from that library and fill only the fields the template allows, such as a greeting or a choice between pre-approved paragraphs. This keeps field email consistent with what MLR signed off, while letting reps follow up on a real conversation.
What is a rep triggered email?
A rep triggered email is a message a field representative sends to an HCP, usually after a visit, a call or a request, using an approved template. The rep controls timing and the recipient; the brand controls the words. Veeva’s page also notes that emails can be scheduled and sent on behalf of field users by the home office, which suits launches and event follow-ups.
What the system records
According to Veeva, email activity such as sends, opens and click-throughs is captured and recorded in Vault CRM. That puts field email data next to call notes, which is useful for planning the next visit. Treat opens with care, for the privacy reasons covered in the measurement section below.
Where Progression fits around Veeva Approved Email
Your Veeva administrators configure the CRM, and your reviewers approve content in your review system. We write and design the templates and content modules, prepare the review packets, test rendering and build the home office sends that sit alongside rep email. We do not claim a Veeva partnership or certification; the work is content, design and program management.
| Question | Home office email | Rep triggered email |
|---|---|---|
| Who chooses the recipient | The brand team, by segment | The rep, from the HCPs they call on |
| Who chooses the timing | A send calendar | The rep, after a visit or request |
| What can change | Nothing after approval | Only fields the template allows |
| Typical tool | An email service connected to the CRM | Veeva Approved Email or a similar CRM tool |
| Best use | Launches, new data, access updates | Follow-up, resources, sample and meeting offers |
| Main risk | Too frequent for a specialty | Too many near-duplicate templates in review |
Patient support and adherence email
Patient program email goes only to people who enrolled, says what the program is and what it is not, and follows the program’s terms. It helps people start and stay on therapy their prescriber chose; it does not sell the product to them.
Enrollment and consent come first
The consent screen and the welcome email decide everything that follows. They should say who runs the program, what messages the person will get, how often, and how to stop. Keep that record with the date, the channel and the program version, so any later question about a message can be answered from the file.
Onboarding, refill and copay messages
A useful sequence covers how to activate a savings card, what to expect from the specialty pharmacy, how to reach a nurse line if the program has one, and when refills are due. Every message is written inside the program terms and the product’s approved information, and reviewed like any other piece that names the product.
When HIPAA applies
Whether HIPAA applies depends on whose data a program uses: data that comes from a pharmacy, provider or plan may be protected health information. Under 45 CFR 164.508, a covered entity needs a patient’s authorization to use or disclose that information for marketing, apart from face-to-face communication and promotional gifts of nominal value. Your privacy team decides how that maps to each data flow; this page is not legal advice.
Patient email does not replace the prescriber
Program emails point people back to their prescriber or pharmacist for any question about their treatment. They avoid language that could read as medical advice, and they route reported side effects to the manufacturer’s safety reporting process the way your pharmacovigilance team specifies.
Launching a brand and need HCP email ready on approval day?Tell us the indication, the HCP specialties you reach and the email tools you use today. We send a free proposal with a written scope for templates, modules and the review calendar.
How does MLR review shape a pharma email program?
MLR review decides the pace of the whole program. Teams that send well have fewer, better-built pieces in review, each assembled from content already approved.
A claims library and modular content
A claims library lists every approved claim with its reference and the safety language that must accompany it. Modular content turns those claims into reusable blocks: a headline, a data panel, an ISI block, a footer. New emails then reuse approved modules, so reviewers check how blocks are combined rather than every word again. It is the single biggest speed gain we see.
Approved templates and version control
Each template has a version number, an approval date and an expiry date. When a label update or a new indication arrives, every affected module is flagged, revised and resubmitted, and older versions are withdrawn from the rep library and the send platform on the same day.
Review packets that move faster
We submit complete packets: the rendered email on desktop and phone, subject line, preheader, every link destination, alt text and the reference for each claim. Reviewers who see the final piece, not a copy deck, raise fewer rounds of comments.
Does every pharma email need MLR review?
Any email that promotes a product, or that could be read as promotional, goes through the company’s medical, legal and regulatory review. Purely transactional notes, such as a password reset, may follow a lighter internal path set by your compliance team. When in doubt, it goes to review.
FDA rules that reach email
FDA’s prescription drug advertising rules at 21 CFR 202.1 were written with print and broadcast in mind, but their principles apply to promotional email: truthful claims, fair balance and no promotion outside the approved labeling. Your regulatory team makes the final call on each piece; this section is general information, not legal advice.
Email and promotional labeling
The regulation’s list of items treated as labeling under 21 CFR 202.1(l)(2) includes brochures, mailing pieces, bulletins, letters and literature that contain drug information and are sent by or for the manufacturer. We prepare promotional email for review with the same care as those pieces, and your regulatory team confirms how each one is classified.
Fair balance and Important Safety Information in email
Section 202.1(e)(5)(ii) says material lacks fair balance when information on effectiveness is presented in greater scope, depth or detail than the risk information. In an email, that means safety information sits close to the claims, in comparable prominence, rather than in a faint footer the reader never reaches.
No uses outside the approved labeling
Section 202.1(e)(4)(i)(a) bars recommending or suggesting any use that is not in the approved labeling. In email, the risk is often indirect: a subject line, an image or a linked article that implies a population or use the label does not cover. Reviewers check every link destination for that reason.
Form FDA 2253 at first dissemination
Under 21 CFR 314.81(b)(3)(i), an applicant submits specimens of mailing pieces and other labeling or advertising at the time of initial dissemination, with Form FDA 2253 and the product’s current professional labeling. We hand your regulatory team final files ready for that submission.
OPDP and the Bad Ad program
FDA’s Office of Prescription Drug Promotion says its role is to help ensure prescription drug promotion is truthful, balanced and accurately communicated, and its reviewers look at advertising and promotional labeling. FDA also runs the Bad Ad program, which invites reports of potentially false or misleading promotion, including from clinicians who receive it.
| Rule | What it says, in short | What it means in an email |
|---|---|---|
| 21 CFR 202.1(e)(1) | Ads present a true brief summary of side effects, contraindications and effectiveness | Safety information and a prescribing information link travel with product claims |
| 21 CFR 202.1(e)(5)(ii) | Risk information comparable in depth and detail with effectiveness claims | ISI in live text near the claims, not buried |
| 21 CFR 202.1(e)(4)(i)(a) | No suggestion of uses outside the approved labeling | Subject lines, images and links checked for implied uses |
| 21 CFR 314.81(b)(3)(i) | Specimens submitted at first dissemination with Form FDA 2253 | Final files and send dates handed to regulatory |
| 21 CFR 312.7(a) | No promotional claims that an investigational drug is safe or effective | Pre-approval email stays corporate or disease awareness |
Consent, CAN-SPAM, state rules and industry codes
Commercial email law applies to HCP email the same way it applies to any business email. Add consent records and the industry’s own code, and the program has a clear trail for every address.
CAN-SPAM has no business-to-business exception
The FTC’s CAN-SPAM compliance guide says the law makes no exception for business-to-business email, so an email to a physician’s work address is covered. The guide lists accurate header information, honest subject lines, identifying the message as an ad, a valid physical postal address, a clear way to opt out, and honoring opt-outs within 10 business days.
Penalties and transactional messages
The same guide says each separate email in violation is subject to penalties of up to $53,088. Messages whose primary purpose is transactional or relationship content are exempt from most provisions, but the FTC reads those categories narrowly, so a newsletter to an HCP is not transactional just because the reader signed up.
Where state email laws still apply
Under 15 U.S.C. 7707(b)(1), CAN-SPAM supersedes state laws that expressly regulate commercial email, except where a state law prohibits falsity or deception in a commercial email. State consumer protection and privacy laws can still reach the data behind a program, which is why your privacy counsel signs off on the consent design.
The PhRMA Code
PhRMA’s Code on Interactions with Health Care Professionals is a voluntary code that focuses on interactions with HCPs that relate to marketing products. PhRMA says it was last updated in August 2021, effective January 1, 2022. Companies that adopt it apply it alongside FDA rules when planning what an HCP email offers or invites.
HCPs outside the United States
EU and UK rules on medicine promotion and electronic marketing differ from US rules. Our pharma SEO page sets out the EU and UK promotion positions at a process level; for email, each market’s consent and promotion rules are confirmed by your local regulatory and privacy teams before a send.
| Item | What we set up | Why it matters |
|---|---|---|
| Opt-in record | Date, source, wording shown and channel for each address | Answers any question about why someone received it |
| Professional verification | Match to a verified professional record your data provider licenses | Keeps patient-facing content apart |
| Sender identity | Brand, company and postal address in every footer | A CAN-SPAM requirement |
| Opt-out | A visible link and a suppression list shared across tools | Opt-outs honored within 10 business days |
| One-click unsubscribe | List-Unsubscribe headers on marketing sends | Required by Gmail for bulk senders |
| Preference center | Topic and frequency choices | Fewer full unsubscribes |
Where email sits in HCP marketing
HCP marketing is every channel a manufacturer uses to reach prescribers: field reps, medical education, paid media on professional networks, conferences, websites and email. Email is the channel that carries a conversation between those moments.
What is HCP marketing, in one line?
It is the planned promotion of a product or disease area to licensed clinicians, inside FDA rules and the industry’s code. Advertising is one part of it, and our pharma advertising page covers HCP paid media and verified audiences, where most HCP engagement programs start.
Email between rep visits
Many practices limit rep access, so email carries much of the follow-up: a resource after a lunch, a reply to a coverage question, a reminder about a speaker program. Plan email so it supports the rep’s calendar rather than competing with it.
How email connects to web and search
Every email points somewhere: a dosing page, an access hub, the prescribing information. Those pages need to load fast, sit behind the right professional gate and answer the question the email raised. Our pharmaceutical marketing page describes how branded and unbranded programs fit together across channels.
Segmenting by specialty, prescribing data and channel preference
Good segments are few and meaningful: specialty, role, care setting and how each person prefers to hear from the brand. More segments mean more versions in review, so every split has to earn its place.
Specialty and role
An oncologist, an oncology nurse navigator and a specialty pharmacist want different things from the same launch. Write for the role first, then adjust the clinical depth by specialty.
Prescribing data, where your license allows
Some brands license prescribing data to prioritize outreach. Its use is governed by the data license and your compliance policies, and it should shape who receives a message and when, never appear as a personal reference inside the email.
Channel preference and frequency
Some clinicians prefer rep contact, some prefer email, some only want medical information when they ask. Record the preference, respect it in every tool, and cap sends per specialty so the brand does not crowd one inbox from three directions.
| Segment | What changes in the email | Review impact |
|---|---|---|
| Prescriber specialty | Clinical depth, data shown, resources linked | One version per specialty in review |
| Nurse and practice staff | Access, onboarding and administration detail | Separate claims set, often fewer claims |
| Pharmacists | Dispensing, storage and supply information | Mostly factual content |
| New to brand | Mechanism, dosing basics and access | Uses core approved modules |
| Current prescribers | New data, support program updates | Reuses modules plus one new block |
| Asked for medical information | Medical response only, no promotion | Medical affairs path, not promotional |
Reps asking for more Approved Email templates than MLR can review?Share how many templates are live and how long review takes now. You get a free proposal for a modular library that cuts the number of new pieces each cycle.
Deliverability to hospital and health system inboxes
Hospital and health system mail is filtered hard, so a pharma email that is approved but never delivered is wasted review time. Authentication, clean lists and light messages do most of the work.
Authentication and bulk sender rules
Google’s email sender guidelines ask senders of more than 5,000 messages a day to Gmail to set up SPF, DKIM and DMARC, support one-click unsubscribe on marketing messages and keep spam rates reported in Postmaster Tools below 0.30 percent. Any HCP who reads mail in Gmail is behind these rules.
Security gateways and link rewriting
Health system mail often passes through security gateways that scan links and can hold messages from unfamiliar domains. Send from a consistent, authenticated brand domain, avoid link shorteners and keep tracking redirects to a minimum.
Light messages and clean lists
Small file sizes, live text, few images and removal of addresses that bounce or never engage keep the program in the inbox. A warm-up plan for a new sending domain protects launch week, when sends spike.
Measuring a pharma email program beyond opens
Measure what a brand team wants HCPs and patients to do: open a resource, request a sample or a rep visit, enroll in a program. Opens are now an unreliable signal on their own.
Why open rates mislead
Apple says its Mail Privacy Protection feature downloads remote content in the background by default, regardless of whether the person engages with the email, and routes it through separate relays. That registers opens that never happened, so pharma email benchmarks built on opens overstate reach.
What to count instead
Clicks to approved resources, prescribing information views, sample and meeting requests from email, medical information questions, program enrollments and unsubscribes by segment. Each ties to a real action and to the version of the email that drove it.
Pharma email open rate and other benchmarks
We do not publish industry benchmark numbers on this page, because published figures mix audiences, privacy-inflated opens and different definitions. We set your own baseline in the first cycle and report change against it by segment and stream.
Biotech email marketing before and after approval
Before approval, biotech email marketing is corporate and disease-awareness work, because the rules forbid promoting an investigational drug. After approval it becomes a brand program with all the rules above.
What the investigational drug rule allows
Under 21 CFR 312.7(a), a sponsor may not represent in a promotional context that an investigational drug is safe or effective for the uses under study, or otherwise promote it. The same rule leaves room for the free exchange of scientific information, such as publications. Email before approval stays on the company, the science and the condition.
Disease awareness and trial recruitment lists
Disease education email to HCPs, and trial recruitment messages approved by the study’s review board, are separate programs from brand email. Keep their lists, consents and templates separate so nothing from one leaks into the other at launch.
Launch readiness
The months before an approval decision are the time to build the claims library structure, templates, consent capture and the sending domain, so the first approved emails can send soon after the label is final. Our life sciences marketing page covers the wider launch plan for emerging companies.
Medical device email marketing
Medical device email marketing speaks to surgeons, nurses, value analysis committees and supply chain teams, in the words the device’s clearance or approval allows.
Claims that match the regulatory pathway
A cleared device and an approved device carry different claim language, and email copy has to match the indications in the clearance or approval. We build device email from the same claims matrix your regulatory team uses for the website and sales materials.
Email for the buying committee
Hospital device purchases involve several roles. Email supports each one with the material that role needs: technique and outcome data for clinicians, cost and contract detail for supply chain. Our medical device marketing page covers the committee in full.
Diagnostics and lab customers
Diagnostics makers email lab directors and clinicians about test menus, turnaround and ordering. The tone is closer to B2B technical email, and our B2B email marketing approach to nurture sequences applies.
How AI assistants answer questions about pharmaceutical email marketing
Brand managers now ask ChatGPT, Claude, Perplexity, Gemini, Copilot and Google AI Overviews which agencies handle pharmaceutical email marketing, how Approved Email works or what MLR review involves. The answers draw on pages that explain those things plainly.
How buyers phrase the question
Typical prompts name the constraint: an agency that understands MLR review, email for a rare disease launch, rep-sent email templates, or a partner who can work with Veeva. Assistants respond with a short list and the reasons, so a page has to state what the provider does in quotable sentences.
What assistants tend to cite
They lean on pages that define terms, regulators’ own pages, comparison tables and FAQs with direct answers. Google says there are no additional requirements or special optimizations needed to appear in its AI features, so the same clear, crawlable pages that rank also get cited.
What a manufacturer should publish
Corporate pages that explain your programs, HCP pages that load quickly behind an appropriate gate, and patient program pages that state terms plainly. Our AEO for pharma page covers how compliant, label-consistent pages earn citations.
How to choose an agency for email marketing for pharma
Choose a team that already writes to MLR standards, can show modular content in practice and reports actions rather than opens. Ask each of them the same questions and compare the answers in writing.
| Requirement | How to check it |
|---|---|
| Writes from an approved claims library | Ask how a new email is drafted and what reviewers receive |
| Builds modular content | Ask to see a module map and how a label change is handled |
| Knows Approved Email templates | Ask how they limit editable fields and template count |
| Handles fair balance and ISI in email | Ask where safety information sits and how it renders with images off |
| Keeps consent records | Ask what is stored for each address and how opt-outs sync |
| Protects deliverability | Ask about SPF, DKIM, DMARC and one-click unsubscribe |
| Measures actions, not opens | Ask for a sample report |
| Owns no list | Confirm they will not supply or rent HCP addresses |
Questions to ask in the first call
How many review rounds does a typical email need with your current clients’ teams? What happens when a label changes on a Friday? How do you keep rep templates from multiplying? What do you report in month one? Clear, specific answers matter more than a long list of tools.
Signs a partner is not ready for life sciences email marketing
A pitch built on open rates, a proposal to buy a list, design that hides safety information in an image, or no mention of review time at all. Each suggests the team has not run regulated email before.
What Progression delivers, and what your MLR team owns
We handle strategy, writing, design, builds, testing, review packets and reporting. Your medical, legal and regulatory reviewers approve content, your regulatory team submits it, and your privacy team owns consent design.
| Task | Progression | Your team |
|---|---|---|
| Email strategy and send calendar | Draft and maintain | Approve |
| Copy and design from approved claims | Write and design | Supply claims library and references |
| Review packets | Prepare and track | Medical, legal and regulatory review |
| Approved Email templates | Write, design, test | Configure in CRM, approve, release |
| Form FDA 2253 submission | Provide final files and dates | Submit |
| Consent and data | Implement in the tools | Design with privacy counsel |
| Safety reports from replies | Route as instructed | Pharmacovigilance process |
| Reporting | Monthly by stream and segment | Review and set priorities |
Tools we work in
Most programs pair a CRM with an email service. We build in the email platform your company already licenses and work alongside your CRM team; our marketing automation and CRM development pages cover integration work if a connection is missing.
Landing pages behind the email
Where an email needs a new destination, such as a resource page or an enrollment form, we build it to the same review standard. Our landing page design team handles the page; your reviewers approve it with the email.
How much does pharma email marketing cost?
A pharma email program is quoted after a written scope, because the number of streams, segments, templates and review cycles decides the work. The related services below use Progression’s published prices.
| Work | Price | Notes |
|---|---|---|
| Pharma email program: strategy, templates, modules, sends, reporting | Quoted after a written scope | Scope depends on streams, segments and review cycles |
| Initial review of your current email program | Free initial audit: $0 | A starting review before any proposal |
| Analytics and conversion tracking implementation | From $2,400 | One-off; connects email clicks to site actions |
| Single landing page for an email destination | From $1,400 | 1 to 2 weeks; one template, copy, form and tracking |
| SEO retainer for the pages email points to | From $1,500 a month | We do not work below about $1,500 a month |
One-off prices come from our SEO services pricing list, the landing page price from website design and development, and the retainer floor from SEO services. General email program scope is described on our email marketing service page. We do not guarantee prescriptions, enrollments or revenue.
What changes the quote
The number of brands and indications, how many specialties need their own version, whether rep templates are in scope, how many languages are needed, and your review calendar. A single-brand HCP program with one patient sequence is a very different scope from a portfolio program.
How a program runs
We audit lists, consent records, templates and the claims library first, then agree segments and a module plan, then send the first review packets. First sends usually follow in weeks eight to ten, depending on how quickly review cycles run.
Get an HCP email program built for MLR review
Tell us the brand, the indication, the HCP specialties you reach and the tools you use. We reply with a free proposal and a written scope covering templates, modules, review packets and reporting.
Patient support program emails sitting in a vendor’s default sequence?Send the program terms and the current messages. We reply with a free proposal for an enrollment and adherence sequence your privacy and regulatory reviewers can sign off.
Related services for pharma, biotech and device teams
These pages cover the channels and topics around email, so this page does not repeat them.
- Pharmaceutical marketing agency: branded and unbranded programs
- Pharma advertising agency: HCP and consumer paid media
- Pharma SEO agency: search for brand, HCP and corporate sites
- Pharma branding agency
- AEO for pharma: being cited by AI assistants
- Life sciences marketing agency
- Medical device marketing
- Email marketing service: flows, campaigns and deliverability
- B2B email marketing agency
- Marketing automation agency
- Email marketing examples worth studying
- Healthcare advertising agency
- Marketing analytics agency
Getting found in search
AI, AEO and what is changing
Paid media and lead generation
Websites and design
Choosing and working with an agency
Software and app development
Website design by industry and type
Web development, platforms and hosting
Social, content and brand
By industry and by situation
Frequently asked questions
What does pharma email marketing cover for a drug or device brand?
What is HCP email?
Is email marketing allowed for pharmaceutical companies?
What is Veeva Approved Email?
What is a rep-triggered email in pharma?
Does every pharma email need MLR review?
How should fair balance and ISI appear in an email?
What are pharma email best practices?
Do pharma emails to physicians fall under CAN-SPAM?
Does a pharma email need to be submitted to FDA?
Can a pharma company buy an HCP email list?
Why are open rates unreliable for pharma email?
How is biotech email marketing different before approval?
How does medical device email marketing differ from drug email?
Does HIPAA apply to pharma email marketing?
What does the PhRMA Code mean for HCP email?
How often should a brand email an HCP?
How do you improve pharma email deliverability to hospitals?
What should a pharma email program report each month?
How many weeks before a new pharma email program sends its first HCP email?
How is pharma email marketing priced, and what does Progression charge?
Can Progression work with our existing MLR and CRM tools?
Launching a brand and need HCP email ready on approval day?Tell us the indication, the HCP specialties you reach and the email tools you use today. We send a free proposal with a written scope for templates, modules and the review calendar.
Get a free marketing proposal
Tell us what you are trying to grow and we will come back with a plan, not a pitch deck. Same-day reply on weekdays.